Phototherapy for Neonatal Jaundice: Devices That Care for Tiny Skin

Every year, roughly six in ten newborn babies develop some degree of jaundice in the first days of life. Bilirubin, a yellow pigment produced by the breakdown of red blood cells, accumulates faster than an immature liver can clear it, leaving the skin mottled gold and the sclera briefly stained. In most cases the rise is physiological and harmless, settling as feeding and gut motility mature. But in some infants the bilirubin load outpaces the body's ability to conjugate and excrete it, pushing serum levels into a range where the pigment can cross into the brain. Severe, untreated neonatal hyperbilirubinemia can lead to acute bilirubin encephalopathy and, in its chronic form, kernicterus, with permanent auditory and motor sequelae.

For more than sixty years, blue light has been the workhorse treatment. Rhoda Foerster's observation that sunlight bleached bilirubin-stained serum launched engineering refinements that range from fluorescent tubes and halogen arrays to the light-emitting diode (LED) systems now found beside most cots in Australian special care nurseries. Each generation has delivered more usable light at lower heat, narrower wavelengths, and longer component life. The trade-off, easy to overlook in the rush to lower bilirubin, is the surface it falls on. A newborn's stratum corneum is thin, the skin-to-body-weight ratio is enormous, and barrier function is still developing. Phototherapy is effective precisely because it penetrates and alters bilirubin in the skin; the same qualities make thoughtful skin protection a clinical necessity rather than a cosmetic extra.

This article walks through the phototherapy devices now used across Australian perinatal centres, the practical skin-protection steps paired with each, and the way local guidelines shape day-to-day decision-making. The aim is to support clinicians, midwives, and neonatal nurses who manage jaundiced infants in tertiary NICUs, in regional units from Townsville to Bunbury, and in the community follow-up that follows discharge.

Australia offers a useful vantage point. Its neonatal population is geographically dispersed, its climate ranges from the alpine chill of Canberra to the tropical humidity of Cairns, and its multicultural demographics include higher rates of glucose-6-phosphate dehydrogenase deficiency and hereditary spherocytosis in some communities. These factors influence both device choice and skin-care planning in small but important ways.

Understanding Bilirubin Build-Up in the Newborn

Bilirubin metabolism in the neonate is a moving target rather than a static problem. Haemoglobin from fetal red cells, which circulate at higher concentrations and shorter lifespans than adult cells, breaks down to produce unconjugated (indirect) bilirubin. The liver takes up this molecule, conjugates it with glucuronic acid via uridine diphosphate-glucuronosyltransferase, and excretes the water-soluble product into bile. Hepatic conjugation enzymes reach adult activity only after the first ten to twelve weeks of life, so a transient imbalance is normal. Cephalohaematoma, sepsis, cold stress, and delayed feeding can all tip that balance toward pathology.

Risk stratification in Australian units typically follows the hour-specific bilirubin nomogram adapted from the Bhutani curves, cross-referenced with resources such as the NSW Health jaundice pathway and the Queensland Paediatric Guideline. A term infant at 38 weeks who crosses the high-intermediate zone at 72 hours usually receives intensified feeding support and a serum bilirubin check within hours, while one who crosses the high zone is admitted for treatment. The same hour-specific threshold differs for late-preterm infants, where neurotoxicity can occur at lower absolute numbers and where skin assessment is harder because of increased translucency.

Identifying infants who need urgent treatment before the first jaundice check leaves the nursery is a recurring safety priority, particularly for babies discharged before day three. Parents are taught to recognise cephalocaudal progression of yellow staining and to wake the baby for feeds, because lethargy and poor intake compound bilirubin rise. Public-health tools, including the personal health record used in Victoria and the red flags highlighted in WA Country Health protocols, reinforce this simple surveillance at home.

Phototherapy Devices Compared for Australian Settings

Choosing a device is no longer a single-vendor decision. Modern special care units across Sydney, Melbourne, Adelaide, and Perth commonly keep at least two modalities on the shelf, matching tool to clinical picture. Conventional overhead LED units remain the mainstay for intensive treatment because they deliver the highest irradiance over a wide field. Fiberoptic blankets shine from below, freeing the baby's hands for comfort feeding and parental touch. Hybrid units stack an overhead panel over a fibre-optic mattress for refractory cases, and turret-style banks can be angled around an incubator.

Each device carries a specific skin-protection implication. Overhead LEDs demand a closed eye shield to prevent retinal photochemical injury, and the heat load of older fluorescent models is now largely a solved problem with solid-state diodes running cool. Fibre-optic pads still expose the ventral skin to room air and partial ambient lighting; any emollient applied must be fully absorbed before placement to avoid pooling and maceration. Hybrid systems intensify the dosage and therefore shorten the margin for unrecognised burns in pigmented skin or under transparent adhesive sensors. Australian equipment standards (AS/NZS 3200 series) require that irradiance and wavelength be verified at commissioning and at least annually, a routine usually embedded in biomedical engineering audits.

Skin Protection Principles During Treatment

Light that breaks down bilirubin in the dermis is not selective. It also affects melanocytes, transiently suppresses vitamin D synthesis, and can disrupt the lipid matrix of the stratum corneum when devices run at high intensity for days. A practical skin-protection programme starts with the eye shield, fitted snugly over closed lids without pressing on the bridge of the nose, and repositioned at every cares cycle to prevent pressure marks. Eye shields should never sit on the cornea directly, and reflectivity should be checked because worn patches let stray light reach the pupil even when the infant appears covered.

Beyond the eyes, the rest of the skin deserves attention equal to that given to bilirubin levels. Cleansing with warm water rather than alcohol-based wipes preserves the vernix and acid mantle. If a lubricant is needed for dryness, water-based paraffin-free products are preferred to avoid pooling under the radiant heat of older units. Sensor sites (pulse oximeter, temperature probe, ECG leads) are rotated and the skin beneath them checked every shift, especially in preterm infants whose dermis can tear under shear. When blue-light phototherapy is interrupted for feeds, the skin is quickly inspected for erythema, pressure marks from positioning aids, and any area where a nappy crease has held moisture.

Phototherapy often suppresses the visible cues of clinical deterioration, hiding cyanosis, mottling, and the early flush of sepsis beneath an even blue glow. Australian nurses therefore build explicit "unmasking" routines into cares: a brief pause every six to twelve hours during which the lights are switched off and the baby is examined in neutral white light. This pause is also a chance to reposition, perform skin-to-skin contact with the parent if haemodynamics allow, and recheck eye-shield fit, a small but valued ritual in many NICUs from Liverpool (NSW) to Fiona Stanley (WA).

Australian Practice, Climate, and Community Context

Australian clinical guidelines, drawn largely from National Health and Medical Research Council consensus statements and adapted by individual state health services, recommend intensive phototherapy for term infants whose serum bilirubin approaches 25 mg/dL (428 µmol/L) or crosses lower thresholds for risk factors. Devices in tertiary centres are routinely calibrated in line with AS/NZS standards, while regional and remote units supported by the Royal Flying Doctor Service often rely on transcutaneous bilirubinometers for initial screening before retrieval or in-situ treatment.

Climate adds a layer not always covered in temperate-zone protocols. Hot, humid conditions in far north Queensland accelerate insensible water loss and can quickly produce dehydration in a feeding infant whose intake is being supported rather than freely demanded. Higher environmental UV index awareness, a strength of Australian public-health messaging, prompts staff and parents to apply sun-safe principles to siblings at home even when the treated infant remains under phototherapy indoors. Skin-care guidance for parents commonly emphasises loose cotton clothing, avoidance of fragranced products, and prompt attention to rashes in the nappy area because such rashes can mimic or mask early signs of treatment-related irritation.

Cultural and linguistic diversity also shapes consent and education. Interpreter services, written materials translated into Mandarin, Vietnamese, Arabic, and Dinka, and partnerships with Aboriginal and Torres Strait Islander health liaison officers influence how skin-care advice is discussed at the bedside. The Perinatal Society of Australia and New Zealand has highlighted gaps in culturally safe discharge planning for Indigenous families, including the practical need for parents to recognise skin changes and access timely readmission.

Preterm and Low-Birth-Weight Infants

Preterm infants represent both the highest-benefit and the highest-risk group for phototherapy. Their low bilirubin-albumin binding, immature blood-brain barrier, and thin skin make treatment thresholds lower and the urgency greater, especially in the first 72 hours. At the same time, skin integrity is fragile: the stratum corneum may not fully form until around 30 weeks of gestation, transepidermal water loss is high, and pressure injuries can develop within hours under positioning aids.

For these babies, devices with the lowest possible heat load and the gentlest irradiation pattern are preferred. Fibre-optic pads are often the initial choice because they leave the infant accessible for clinician observation and parent touch, while overhead LEDs can be added or swapped in once bilirubin trends are clear. Eye shields for preterm infants must be sized specifically, because generic shields slip and create pressure points over the nasal bridge; many Australian units stock a small range and check fit at every cares. Limbs are tucked rather than restrained, and adhesives are avoided unless absolutely necessary.

Long-term outcomes continue to inform how aggressively borderline jaundice is treated. Studies of long-term neurodevelopmental outcomes in preterm infants show that the cost of overtreatment (longer hospital stay, disrupted breastfeeding, maternal separation) and the cost of undertreatment (subtle auditory processing deficits) both deserve considered thresholds rather than reflexive lower-is-better thinking.

Safety Monitoring, Documentation, and Going Home

Continuous monitoring is the thread that ties device selection and skin protection together. Irradiance metres are checked at every shift, the eye shield is examined every four hours, and the skin is mapped at every cares cycle, often with a simple body-area chart that lets the next clinician spot new areas of erythema. Bilirubin is rechecked at intervals dictated by the rate of fall and the infant's age in hours, with pauses to feed and re-unite with parents built into the schedule wherever safe.

Discharge planning is where skin-care education translates from textbook to lived routine. Parents are taught to look at the infant in natural daylight, because home lighting can both exaggerate and hide jaundice, and to use the transcutaneous bilirubinometer if one has been issued. They are also taught when to call: a return of deep yellow staining to the legs, refusal of feeds, lethargy, or any new rash, particularly around the nappy edges, deserves same-day review.

The dilemmas of extreme prematurity, where jaundice sits alongside choices about resuscitation, ventilation, and the limits of care, overlap with the ethical dilemmas in extreme prematurity management discussed at recent regional meetings. Bringing skin-care thinking into those wider conversations keeps the smallest, most overlooked surface in the room.

Browse the latest resources available through the FAOPS 2020 congress website for the related scientific programme, abstracts, and recorded sessions on neonatal jaundice, phototherapy, and skin integrity. Continued engagement with the global perinatal community keeps Australian practice evidence-based and patient-centred, and every clinician who treats jaundiced newborns can contribute to that shared knowledge base.